Jazz Pharmaceuticals announces $400M increase to share repurchase program

Jazz Pharmaceuticals announced that its Board of Directors has authorized a $400M increase in the company’s share repurchase program, which the company intends to use over time based on market conditions and other factors. Prior to this increased authorization, the Board of Directors had authorized $620M under the company’s share repurchase program, of which $194M had been utilized through September 30, 2018. Since that date, the company has utilized the remainder of that prior authorization.
https://thefly.com/landingPageNews.php?id=2834859